1y return+80.1%S&P 500 +20.9%
3y return+148.4%S&P 500 +68.5%
5y return+124.8%S&P 500 +74.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since March 31, 2018: $434 against $284 in the S&P 500.2
Sofinnova Investments, Inc.S&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| NTRANatera Inc | $420.8M | 22.5% | |
| VERAVera Therapeutics Inc | $119.9M | 6.4% | |
| GMABGenmab A/S | $111.1M | 5.9% | +437.7% |
| Jazz Pharmaceuticals PLCCUSIP G50871105 | $88.0M | 4.7% | −38.9% |
| RAPPRapport Therapeutics Inc | $79.4M | 4.2% | |
| SPTXSeaport Therapeutics Inc | $77.4M | 4.1% | New |
| AVBPArrivent BioPharma Inc | $58.9M | 3.1% | |
| RAREUltragenyx Pharmaceutical In | $57.3M | 3.1% | −45.4% |
| BIOABioAge Labs Inc | $56.2M | 3.0% | |
| BMYBristol-Myers Squibb Co | $50.5M | 2.7% | −55.9% |
| SUPNSupernus Pharmaceuticals | $48.2M | 2.6% | +8.6% |
| RYTMRhythm Pharmaceuticals Inc | $45.3M | 2.4% | −9.3% |
| GILDGilead Sciences Inc | $43.3M | 2.3% | New |
| UTHRUnited Therapeutics Corp Del | $41.4M | 2.2% | −52.2% |
| COGTCogent Biosciences Inc | $40.1M | 2.1% | −51.0% |
| AXSMAxsome Therapeutics Inc. | $39.3M | 2.1% | −24.6% |
| Immatics N.VCUSIP N44445109 | $37.2M | 2.0% | +1.1% |
| DYNDyne Therapeutics Inc | $36.8M | 2.0% | +1.5% |
| IMNMImmunome Inc | $36.5M | 1.9% | +1.1% |
| IDYAIDEAYA Biosciences Inc | $34.5M | 1.8% | −18.3% |
| ANABAnaptysbio Inc | $33.3M | 1.8% | +98.8% |
| NKTRNektar Therapeutics | $32.9M | 1.8% | −7.4% |
| Pharvaris N VCUSIP N69605108 | $30.5M | 1.6% | +7.7% |
| RCUSArcus Biosciences Inc | $29.2M | 1.6% | +2.4% |
| INBXInhibrx Biosciences Inc | $28.7M | 1.5% | −25.3% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| INBXInhibrx Biosciences Inc | June 30, 2024 | +568.7% | $28.7M |
| COGTCogent Biosciences Inc | March 31, 2024 | +475.9% | $40.1M |
| NTRANatera Inc | June 30, 2020 | +444.4% | $420.8M |
| ANABAnaptysbio Inc | December 31, 2024 | +409.8% | $33.3M |
| RCUSArcus Biosciences Inc | March 31, 2025 | +292.7% | $29.2M |
| VERAVera Therapeutics Inc | June 30, 2021 | +223.8% | $119.9M |
| AXSMAxsome Therapeutics Inc. | June 30, 2024 | +204.1% | $39.3M |
| IDYAIDEAYA Biosciences Inc | September 30, 2022 | +149.8% | $34.5M |
| DFTXDefinium Therapeutics Inc | March 31, 2026 | +148.9% | $12.0M |
| EWTXEdgewise Therapeutics Inc | June 30, 2024 | +125.6% | $15.5M |
Sold off last quarter
- AstraZeneca PLCCUSIP G0593M107 was $89.9M
- BIIBBiogen Inc was $42.1M
- CELCCelcuity Inc was $41.8M
- BBIOBridgeBio Pharma Inc was $30.4M
- DXCMDexcom Inc was $24.7M
- XENEXenon Pharmaceuticals Inc was $17.7M
- SYKStryker Corporation was $14.6M
- Roivant Sciences LtdCUSIP G76279101 was $13.2M
- CMPXCompass Therapeutics Inc was $10.9M
- ORICOric Pharmaceuticals Inc was $8.6M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +14.8% | +14.8% |
| March 31, 2026 | −0.1% | −4.6% |
| December 31, 2025 | +33.3% | +2.4% |
| September 30, 2025 | +17.9% | +7.8% |
| June 30, 2025 | +8.4% | +10.5% |
| March 31, 2025 | −9.6% | −4.6% |
| December 31, 2024 | −5.8% | +2.1% |
| September 30, 2024 | +4.8% | +5.4% |
| June 30, 2024 | −1.7% | +4.0% |
| March 31, 2024 | +18.8% | +10.0% |
| December 31, 2023 | +41.0% | +11.2% |
| September 30, 2023 | −13.5% | −3.6% |
| June 30, 2023 | +11.0% | +8.3% |
| March 31, 2023 | −2.3% | +7.0% |
| December 31, 2022 | −5.3% | +7.1% |
| September 30, 2022 | +32.6% | −5.3% |
| June 30, 2022 | −8.1% | −16.5% |
| March 31, 2022 | −19.4% | −4.9% |
| December 31, 2021 | −8.9% | +10.7% |
| September 30, 2021 | −1.6% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Sofinnova Investments, Inc. Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1631134&type=13F-HR&dateb=&owner=include&count=40CIK 1631134
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1631134/000110465926096982/Filed August 14, 2026 · accession 0001104659-26-096982